Suzhou Suncadia Biopharmaceuticals Co., Ltd.
PharmaSuzhou, Jiangsu, China · Est. 2010
Suzhou Suncadia Biopharmaceuticals is a Chinese biopharmaceutical company focused on developing innovative drugs for oncology and other therapeutic areas.
31
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
32
Indications↗
Distinct diseases across all programs
120
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
31 drugs in development
Phase 38
Phase 221
Phase 13
Preclinical5
By Therapeutic Area
top 3
Oncology
2670%
Musculoskeletal
13%
Immunology
13%
R&D Momentum
82/100
Pipeline Velocity
58/100
Trial Completion Rate
62/100
Pipeline Concentration
55/100
Pipeline Freshness
82/100
Strategic Signals
- ↗Active in Musculoskeletal but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Earlier
Oct 8, 2026TrialAn Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer.
Oct 6, 2026TrialA Phase I Clinical Study of SHR-4685 on Safety, Tolerability and Pharmacokinetics in Participants With Solid Tumors
Sep 26, 2026TrialA Randomized, Controlled, Open-label, Multicenter Phase III Clinical Study of Anti CTLA-4 Antibody SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the First-line Treatment of Advanced Hepatocellular Carcinoma (KYLIN-02)
Sep 26, 2026TrialA Phase 3, Open-label, Randomized Study of SHR-A1912 Combined With Rituximab + Gemcitabine + Oxaliplatin (R-GEMOX) Versus R-GEMOX in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Sep 26, 2026TrialA Randomized, Open-label, Multicenter, Phase III Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib as First-line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutations
Sep 24, 2026TrialA Clinical Study of the Safety and Tolerability of SHR-1901 in Subjects With Advanced Malignant Tumors
Sep 17, 2026TrialA Randomized, Controlled, Open-label, Multicenter Phase II Clinical Study of SHR-9839 as Monotherapy or in Combination With Chemotherapy Plus Adebrelimab Versus Chemotherapy Plus Adebrelimab in Patients With Advanced Esophageal Squamous Cell Carcinoma
Details
Company Info
Therapeutic Focus
oncologyimmunologyrare diseases
Pipeline
Drug Pipeline
Therapeutic Area
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Immunology(1 drug)
—
—
—
1
—
Immunology(1 drug)
Musculoskeletal(1 drug)
—
—
—
1
—
Musculoskeletal(1 drug)
Oncology(26 drugs)
5
3
17
7
—
Oncology(26 drugs)
Unknown / Other(9 drugs)
—
1
9
—
—
Unknown / Other(9 drugs)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)